TORONTO, Oct. 12, 2022 (GLOBE NEWSWIRE) — Reunion Neuroscience Inc. (TSX: REUN, NASDAQ: REUN) (“Reunion” or the “Company”), a leader in novel serotonergic psychedelic drug development committed to innovating proprietary therapeutic solutions for mental health conditions, announced today that the Company’s President and CEO, Mr. Greg Mayes, will participate on a panel at this year’s Horizons Perspectives on Psychedelics conference, taking place at the New York Academy of Medicine in New York City.
The panel session, titled, “Raising Capital for Psychedelic Endeavors,” is part of the conference’s Psychedelic Business Forum and will focus on how both companies and funds are raising capital to expand their business interests in the growing field of psychedelic medicine. The panel will take place on Thursday, Oct. 13, 2022, at 2:30 p.m. ET.
“There is a clear and urgent need to address the ongoing mental health crisis that plagues society today, and science has proven that psychedelic medicine may be key to developing the next generation of effective CNS treatments,” said Mr. Mayes. “As such, it is vital that we think about psychedelics as an important component to mental health treatment in much the same way that we evaluate the use of traditional therapeutics. The evidence supporting the success of psychedelic treatment across a wide range of psychiatric conditions continues to evolve, and these promising therapies deserve both attention and investment. This is an important conversation to have to set the record straight, and I look forward to exploring this topic more in-depth at Horizons to further raise awareness.”
Presented by Horizons PBC, a public benefit corporation, the Perspectives on Psychedelics conference is the largest and longest-running annual gathering of the psychedelic community in the world. Its Psychedelic Business Forum explores the psychedelic economy and industry for executives, entrepreneurs and funders.
About Reunion Neuroscience Inc., (formerly, Field Trip Health Ltd.)
Reunion is a leader in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The Company’s lead asset, RE-104 (previously known as FT-104), is a proprietary, novel serotonergic psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. Reunion is also developing the FT-200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psychoactivity for potential use in more chronic treatment paradigms and indications.
To be added to the Reunion Neuroscience email list, please email Reunion@kcsa.com with “REUN” in the subject line.
Cautionary Note Regarding Forward-Looking Information
This release includes forward-looking information (within the meaning of Canadian securities laws and within the meaning of the United States Private Securities Litigation Reform Act of 1995) regarding the Company and its business. Often but not always, forward-looking information can be identified by the use of words such as “expect”, “intends”, “anticipated”, “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would” or “will” be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the companies. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Additional information relating to Field Trip, including its Annual Information Form, can be located on the SEDAR website at www.sedar.com and on the EDGAR section of the SEC’s website at www.sec.gov.
Neither Toronto Stock Exchange, or its Regulation Services Provider, have approved the contents of this release or accept responsibility for the adequacy or accuracy of this release.
KCSA Strategic Communications
Phil Carlson / Sophia Bashford
KCSA Strategic Communications
(646) 573-0776 / (929) 246-7307